ES102 not checked

Inhibrx Biosciences · Elpiscience Biopharma · INBRX-106 · Hexavalent OX40 agonist antibody

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“INBRX-106 0.1 mg/kg by intravenous (IV) infusion, given every 3 weeks (QW3)”In the company’s words, NCT06295731 on ClinicalTrials.gov
Tested for
Non-Small Cell Lung Cancer (2 trials), Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC), Solid Tumor, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma and 2 more
Main trialPhase 2/3
“This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with recurrent or metastatic (R/M) HPV-positive Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) expressing PD-L1.”In the company’s words, NCT06295731 on ClinicalTrials.gov
Other names
INBRX-106 · Hexavalent OX40 agonist antibody · Ordastobart

Other drugs for Non-Small Cell Lung Cancer

All 560 drugs for Non-Small Cell Lung Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting Dec 2029 Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Phase 2Active, not recruiting 28 Feb 2027 A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2Recruiting Jul 2033 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Phase 1Completed 1 Mar 2024 A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
Phase 1Completed 17 May 2024 A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ES102

Following is part of Solo: you see every change to ES102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in